Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2003-05-26
2008-09-02
Landsman, Robert (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07419955
ABSTRACT:
A scavenger receptor A expression down-regulator and a drug for preventing or treating arteriosclerosis which contain, as the active ingredient, a C-terminal globular domain of adiponectin, adiponectin, or a gene encoding the domain or adiponectin. According to the present invention, there is provided a preventive or therapeutic agent capable of directly preventing intimal thickening, which constitutes an essential feature of arteriosclerosis. This effect can be attained through arresting the onset and development of arteriosclerosis by reducing the expression level of scavenger receptor A in arterial walls and preventing lipid buildup in macrophages.
REFERENCES:
patent: 6344441 (2002-02-01), Bihain et al.
patent: 1033134 (2000-09-01), None
patent: WO 99/07736 (1999-02-01), None
patent: 02/061076 (2002-08-01), None
Arteriosclerosis/atherosclerosis (MayoClinic.com).
Ouchi, Noriyuki et al., Adipocyte-dervied plasma portel, adiponectin, suppesses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrohages, Circulation, vol. 103, No. 8, pp. 1057 to 1063, 2001.
Ouchi, Noriyuki et al., A novel adipocyte-derived plasma protein, adiponectin, suppreses scavenger receptor expression in human monocyte-derived macrophages., Circulation, vol. 110, No. 18, Suppl., pp. I.751. Meeting Info. : 72ndScientific Sessions of the America Heart Association, 1999.
Kihara, Shinji et al., Anti-atherogenic property of adipocyte-derived plasma protein adiponectin., Journal of Molecular and Cellular Cardiology, vol. 32, No., pp. A93, 2000.
Maeda, Kazuhisa et al., cDNA cloning and expression of a novel adipose specific collagen-like fector, apM1 (adipose most abundant gene transcript 1), Biochemical and Biophysical Research Communications, vol. 221, No. 2, pp. 286 to 289, 1996.
Okamoto, Yoshihisa et al., Adiponectin Reduces Atherosclerosis in Apolipoprotein E-Deficient Mice, Circulation, vol. 106, No. 22, pp. 2767-2770, Nov. 26, 2002.
U.S. Appl. No. 10/514,716, filed Nov. 23, 2004, Kadowaki et al.
U.S. Appl. No. 10/514,715, filed Nov. 23, 2004, Kadowaki et al.
U.S. Appl. No. 10/502,051, filed Jul. 30, 2004, Kadowaki et al.
Tsu-Shuen Tsao, et al., “ACRP30, a new hormone controlling fat and glucose metabolism”, European Journal of Pharmacology, XP 002319451, vol. 440, No. 2-3, Apr. 12, 2002, pp. 213-221.
Anders H. Berg, et al., “ACRP30/ adiponectin: an adipokine regulating glucose and lipid metabolism”, Trends in Endocrinology & Metabolism, XP 002286670, vol. 13, No. 2, Mar. 2002, pp. 84-89.
Joachim Fruebis, et al., “Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice”, Proceedings of the National Academy of Sciences, XP 002242791, vol. 98, No. 4, Feb. 13, 2001, pp. 2005-2010.
Imai Yasushi
Kadowaki Takashi
Kubota Naoto
Kubota Tetsuya
Nagai Ryozo
Chandra Gyan
Japan Science and Technology Agency
Landsman Robert
Oblon & Spivak, McClelland, Maier & Neustadt P.C.
LandOfFree
Method for treating arteriosclerosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating arteriosclerosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating arteriosclerosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3981681